首页 > 市场调查报告书 > 製药

癌症

多发性骨髓瘤治疗市场规模、份额和成长分析（按治疗方法、给药途径、疾病类型、最终用户和地区划分）—产业预测，2026-2033年

市场调查报告书

商品编码

1898353

多发性骨髓瘤治疗市场规模、份额和成长分析（按治疗方法、给药途径、疾病类型、最终用户和地区划分）—产业预测，2026-2033年

Multiple Myeloma Therapeutics Market Size, Share, and Growth Analysis, By Therapy Type (Chemotherapy, Targeted Therapy), By Route of Administration (Oral, Parenteral), By Disease Type, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球多发性骨髓瘤治疗市场规模将达到 263.6 亿美元，到 2025 年将达到 280.2 亿美元，到 2033 年将达到 456.9 亿美元，预测期（2026-2033 年）的复合年增长率为 6.3%。

由于多发性骨髓瘤这种危及生命的血液癌症的复杂性，以及对骨髓和浆细胞生成的严重影响，全球多发性骨髓瘤治疗市场正经历显着增长。人口老化以及对该疾病分子机制的深入了解，都促进了这个市场的成长。科学技术的进步催生了针对恶性浆细胞的特化且强效的治疗方法，从而改善了患者的治疗效果。干细胞移植、免疫调节药物、蛋白酶体抑制剂、化疗和单株抗体等治疗策略是推动市场成长的关键因素。随着製药公司加强对创新治疗方法和个人化医疗的投资，市场竞争异常激烈。这些公司积极合作，致力于开发疗效较佳、副作用较少的新型治疗方法，例如单株抗体和CAR-T细胞疗法。

推动全球多发性骨髓瘤药物市场发展的因素

全球多发性骨髓瘤治疗市场的发展主要得益于新型先进治疗方法的涌现。研究人员和製药公司正积极开发创新治疗方法，例如单株抗体、蛋白酶体抑制剂和免疫调节药物（IMiDs），这些疗法旨在靶向癌细胞，同时最大限度地减少对正常细胞的损伤。对这些突破性药物的关注正在提高治疗效果，从而改善患者的生存期和治疗后的整体生活品质。这些进展不仅代表癌症治疗的突破，也为与多发性骨髓瘤作斗争的患者带来了希望，并体现了肿瘤治疗的持续发展。

全球多发性骨髓瘤药物市场受到抑制

儘管治疗方案的进步改善了患者的预后，但某些治疗方法的高成本仍然是一大障碍。许多多发性骨髓瘤患者由于经济困难，尤其是在经济资源匮乏或医疗资源不足的地区，难以获得治疗。这些经济限制会阻碍创新疗法的应用，最终阻碍市场成长。因此，这些重要治疗方法的可负担性和可近性仍然是必须解决的关键障碍，只有解决这些问题，更广泛的患者群体才能受益于多发性骨髓瘤治疗的最新进展。

全球多发性骨髓瘤药物市场趋势

全球多发性骨髓瘤治疗市场正呈现出显着的趋势，即标靶治疗和免疫疗法的进步，这主要源自于对更有效、特异性的治疗方法的需求。鑑于传统化疗在疗效和副作用方面的局限性，製药公司正在加速开发能够精准靶向癌细胞并最大限度减少对健康组织损伤的新型治疗方法。这包括开发单株抗体和其他标靶药物，以抑制骨髓瘤细胞的生长和存活。此外，免疫疗法，特别是CAR-T细胞疗法的良好疗效，凸显了精准医疗的趋势，有助于提高多发性骨髓瘤的治疗效果和患者预后。

北美（治疗方法、给药途径、疾病和最终用户划分）
- 美国
- 加拿大
欧洲（治疗方法、给药途径、疾病、最终使用者）
- 英国
- 德国
- 西班牙
- 法国
- 义大利
- 其他欧洲
亚太地区（按治疗方法、给药途径、疾病和最终用户划分）
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲（按治疗方法、给药途径、疾病和最终用户划分）
- 巴西
- 墨西哥
- 其他拉丁美洲
中东和非洲（按治疗方法、给药途径、疾病和最终用户划分）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争对手仪錶板

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）

主要企业简介

F. Hoffmann-La Roche Ltd.
The following companies are listed for indicative purposes only. Similar information will be provided for each, with detailed financial data available exclusively for publicly listed companies.
Bristol Myers Squibb
Takeda Pharmaceutical Company Limited
Amgen Inc.
Sanofi SA
Johnson & Johnson
AbbVie Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Karyopharm Therapeutics Inc.
Ono Pharmaceutical Co., Ltd.
Genmab A/S
Adaptive Biotechnologies Corporation
Legend Biotech Corporation
bluebird bio, Inc.
BeiGene, Ltd.
Merck & Co., Inc.
AstraZeneca plc
Bayer AG

结论和分析师建议

简介目录

Product Code: SQMIG35I2237

Global Multiple Myeloma Therapeutics Market size was valued at USD 26.36 Billion in 2024 and is poised to grow from USD 28.02 Billion in 2025 to USD 45.69 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The global multiple myeloma therapeutics market is experiencing significant growth, driven by the complexities of this life-threatening hematological cancer that affects bone marrow and plasma cell production. The rise in the aging population and increased understanding of the disease at a molecular level have contributed to this expansion. Enhanced scientific advancements are leading to the development of specialized and potent therapies targeting malignant plasma cells, thereby improving patient outcomes. Therapeutic strategies such as stem cell transplants, immunomodulatory drugs, proteasome inhibitors, chemotherapy, and monoclonal antibodies are crucial for market growth. The landscape is highly competitive as pharmaceutical companies invest in innovative treatments and personalized care, fostering collaborations that yield novel therapies like monoclonal antibodies and CAR-T cell therapies with improved efficacy and reduced side effects.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Myeloma Therapeutics Market Segments Analysis

Global Multiple Myeloma Therapeutics Market is segmented by Therapy Type, Route of Administration, Disease Type, End User and region. Based on Therapy Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunomodulating agents, Stem cell transplantation, Radiation therapy and Others. Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on Disease Type, the market is segmented into Smouldering (Indolent) Multiple Myeloma, Active (Symptomatic) Multiple Myeloma, Solitary Plasmacytoma of the Bone, Extrameduallry Plasmacytoma, Light Chain Myeloma, Non-Secretory Myeloma, Rare Types of Myeloma and Others. Based on End User, the market is segmented into Hospitals & Clinics, Cancer Centers, Homecare settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Myeloma Therapeutics Market

The global multiple myeloma therapeutics market is significantly propelled by the emergence of novel and advanced treatment options. Researchers and pharmaceutical companies are actively developing innovative therapies, including monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs (IMiDs), which are designed to target cancer cells while minimizing harm to healthy cells. This focus on breakthrough medications has enhanced the efficacy of treatments, leading to improved patient survival rates and overall quality of life following therapy. Such advancements not only represent a leap in cancer treatment but also foster hope for patients battling multiple myeloma, reflecting the ongoing evolution of oncological care.

Restraints in the Global Multiple Myeloma Therapeutics Market

Despite advancements in therapeutic options that have enhanced patient outcomes, the high cost of certain treatments poses a significant barrier. Many patients encounter challenges in accessing multiple myeloma therapies due to affordability issues, particularly in regions with limited economic resources or inadequate healthcare access. This financial constraint can restrict the adoption of innovative treatments, ultimately impeding market growth. As a result, the affordability and accessibility of these vital therapies represent key obstacles that must be addressed to ensure a broader patient population benefits from the latest advancements in multiple myeloma treatment options.

Market Trends of the Global Multiple Myeloma Therapeutics Market

The Global Multiple Myeloma Therapeutics market is witnessing a significant trend toward the advancement of targeted therapies and immunotherapies, driven by the need for more effective and specific treatment options. As traditional chemotherapy has limitations in both efficacy and side effects, pharmaceutical companies are increasingly developing novel therapies that precisely target cancer cells while minimizing damage to healthy tissues. This includes the creation of monoclonal antibodies and other targeted agents that inhibit the growth and survival of myeloma cells. Furthermore, the promising results from immunotherapies, particularly CAR-T cell therapy, underscore a shift toward personalized medicine, enhancing treatment efficacy and patient outcomes in multiple myeloma management.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Patent Analysis
Clinical Trial
Pipeline Analysis

Global Multiple Myeloma Therapeutics Market Size by Type (2019-2032)

Market Overview
Chemotherapy
- Traditional chemotherapy
- Immunomodulating agents
- Proteasome inhibitors
- Histone Deacetylase (HDAC) inhibitors
- Monoclonal Antibodies
Targeted Therapy
Immunomodulating agents
Stem cell transplantation
Radiation therapy
Others

Global Multiple Myeloma Therapeutics Market Size by Route of Administration (2019-2032)

Market Overview
Oral
Parenteral

Global Multiple Myeloma Therapeutics Market Size by Disease Type (2019-2032)

Market Overview
Smouldering (Indolent) Multiple Myeloma
Active (Symptomatic) Multiple Myeloma
Solitary Plasmacytoma of the Bone
Extrameduallry Plasmacytoma
Light Chain Myeloma
Non-Secretory Myeloma
Rare Types of Myeloma
Others

Global Multiple Myeloma Therapeutics Market Size by End User (2019-2032)

Market Overview
Hospitals & Clinics
Cancer Centers
Homecare settings
Others

Global Multiple Myeloma Therapeutics Market Size (2019-2032)

North America (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- US
- Canada
Europe (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Dashboard

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025

Key Company Profiles

F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio Overview
- Financial Overview
- Key Developments
The following companies are listed for indicative purposes only. Similar information will be provided for each, with detailed financial data available exclusively for publicly listed companies.
Bristol Myers Squibb
Takeda Pharmaceutical Company Limited
Amgen Inc.
Sanofi S.A.
Johnson & Johnson
AbbVie Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Karyopharm Therapeutics Inc.
Ono Pharmaceutical Co., Ltd.
Genmab A/S
Adaptive Biotechnologies Corporation
Legend Biotech Corporation
bluebird bio, Inc.
BeiGene, Ltd.
Merck & Co., Inc.
AstraZeneca plc
Bayer AG